Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial

Kiritsi D, Schauer F, Gewert S, Reineker K, Reimer-Taschenbrecker A, Schwieger-Briel A, Ott H, Schmoor C, Grishina O, Murrell D, Stiller B, Zahn T, Nyström A, Bruckner-Tuderman L. 2024.  Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial. EClinicalMedicine. 2024 Oct 30;77:102900. doi: 10.1016/j.eclinm.2024.102900.

Categorised in:

This post was written by Heike Ufheil